The American drug agency FDA has approved a new drug designed to slow the cognitive decline that occurs in Alzheimer’s patients. The drug is based on a discovery by Swedish researcher Lars Lannfeldt, professor at Uppsala University. It is marketed under the name Leqembi, and contains the antibody lecanemab which targets the protein beta-amyloid. Beta-amyloid is considered by many researchers to be one of the causes of Alzheimer’s disease.
t4-general
The US quickly approves new Alzheimer’s medicine
